InvestorsHub Logo
icon url

DewDiligence

12/07/18 9:50 AM

#222694 RE: DewDiligence #221642

ENTA—Mavyret’s US new-patient share=55.2%—the highest-ever weekly figure—in the week ending 11/30/18, as reported by IMS. GILD’s US new-patient share was 44.2%, and MRK’s was 0.6%%.

Mavyret’s US total-script share was 48.3%, also the highest-ever weekly figure, as reported by IMS. GILD’s US total-script share was 50.9%, and MRK’s was 0.8%.